Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study | Synapse
March 13, 2026Open Access
Stability in Cognition and Employment in People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-year Phase IV CLARIFY-MS Study
Key Points
The study aims to evaluate the effects of cladribine tablets on cognitive function and employment stability in individuals with relapsing multiple sclerosis.
Conducted a phase IV clinical trial over two years.
Assessed cognitive function and employment status of participants.
Utilized specific clinical measures to evaluate outcomes.
Participants exhibited stable cognitive functioning over the study duration.
Employment rates among participants remained stable throughout the trial.
Cladribine treatment was associated with positive outcomes in cognition and employment.